Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Pharm ; 661: 124420, 2024 Jul 05.
Article in English | MEDLINE | ID: mdl-38971512

ABSTRACT

Colorectal cancer represents a worldwide spread type of cancer and it is regarded as one of the leading death causes, along with lung, breast, and prostate cancers. Since conventional surgical resection and chemotherapy proved limited efficiency, the use of alternative drug delivery systems that ensure the controlled release of cytostatic agents possess immense potential for treatment. In this regard, the present study aimed to develop and evaluate the efficiency of a series of irinotecan-loaded magnetite-silica core-shell systems. The magnetite particles were obtained through a solvothermal treatment, while the silica shell was obtained through the Stöber method directly onto the surface of magnetite particles. Subsequently, the core-shell systems were physico-chemically and morpho-structurally evaluated trough X-ray diffraction (XRD) and (high-resolution) transmission electron microscopy ((HR-)TEM) equipped with a High Annular Angular Dark Field Detector (HAADF) for elemental mapping. After the irinotecan loading, the drug delivery systems were evaluated through Fourier-transform infrared spectroscopy (FT-IR), thermogravimetry and differential scanning calorimetry (TG-DSC), and UV-Vis spectrophotometry. Additionally, the Brunauer-Emmett-Teller (BET) method was employed for determining the surface area and pore volume of the systems. The biological functionality of the core-shells was investigated through the MTT assay performed on both normal and cancer cells. The results of the study confirmed the formation of highly crystalline magnetite particles comprising the core and mesoporous silica layers of sizes varying between 2 and 7 nm as the shell. Additionally, the drug loading and release was dependent on the type of the silica synthesis procedure, since the lack of hexadecyltrimethylammonium bromide (CTAB) resulted in higher drug loading but lower cumulative release. Moreover, the nanostructured systems demonstrated a targeted efficiency towards HT-29 colorectal adenocarcinoma cells, as in the case of normal L929 fibroblast cells, the cell viability was higher than for the pristine drug. In this manner, this study provides the means and procedures for developing drug delivery systems with applicability in the treatment of cancer.

2.
Antimicrob Agents Chemother ; 56(9): 4662-70, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22710113

ABSTRACT

The resistance of methicillin-resistant Staphylococcus aureus (MRSA) to all ß-lactam classes limits treatment options for serious infections involving this organism. Our goal is to discover new agents that restore the activity of ß-lactams against MRSA, an approach that has led to the discovery of two classes of natural product antibiotics, a cyclic depsipeptide (krisynomycin) and a lipoglycopeptide (actinocarbasin), which potentiate the activity of imipenem against MRSA strain COL. We report here that these imipenem synergists are inhibitors of the bacterial type I signal peptidase SpsB, a serine protease that is required for the secretion of proteins that are exported through the Sec and Tat systems. A synthetic derivative of actinocarbasin, M131, synergized with imipenem both in vitro and in vivo with potent efficacy. The in vitro activity of M131 extends to clinical isolates of MRSA but not to a methicillin-sensitive strain. Synergy is restricted to ß-lactam antibiotics and is not observed with other antibiotic classes. We propose that the SpsB inhibitors synergize with ß-lactams by preventing the signal peptidase-mediated secretion of proteins required for ß-lactam resistance. Combinations of SpsB inhibitors and ß-lactams may expand the utility of these widely prescribed antibiotics to treat MRSA infections, analogous to ß-lactamase inhibitors which restored the utility of this antibiotic class for the treatment of resistant Gram-negative infections.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacterial Proteins/antagonists & inhibitors , Biphenyl Compounds/pharmacology , Depsipeptides/pharmacology , Glycopeptides/pharmacology , Glycosides/pharmacology , Lipopeptides/pharmacology , Membrane Proteins/antagonists & inhibitors , Methicillin-Resistant Staphylococcus aureus/drug effects , Oligopeptides/pharmacology , Staphylococcal Infections/drug therapy , beta-Lactams/pharmacology , Animals , Anti-Bacterial Agents/isolation & purification , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Biological Transport , Biphenyl Compounds/chemical synthesis , Depsipeptides/isolation & purification , Drug Synergism , Drug Therapy, Combination , Female , Glycopeptides/chemical synthesis , Glycopeptides/isolation & purification , Glycosides/isolation & purification , Humans , Lipopeptides/isolation & purification , Membrane Proteins/genetics , Membrane Proteins/metabolism , Methicillin-Resistant Staphylococcus aureus/genetics , Methicillin-Resistant Staphylococcus aureus/growth & development , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Multigene Family , Oligopeptides/chemical synthesis , Serine Endopeptidases/genetics , Serine Endopeptidases/metabolism , Staphylococcal Infections/microbiology , beta-Lactam Resistance/drug effects , beta-Lactam Resistance/genetics , beta-Lactamases/genetics , beta-Lactamases/metabolism
3.
Sci Transl Med ; 4(126): 126ra35, 2012 Mar 21.
Article in English | MEDLINE | ID: mdl-22440737

ABSTRACT

Despite the need for new antibiotics to treat drug-resistant bacteria, current clinical combinations are largely restricted to ß-lactam antibiotics paired with ß-lactamase inhibitors. We have adapted a Staphylococcus aureus antisense knockdown strategy to genetically identify the cell division Z ring components-FtsA, FtsZ, and FtsW-as ß-lactam susceptibility determinants of methicillin-resistant S. aureus (MRSA). We demonstrate that the FtsZ-specific inhibitor PC190723 acts synergistically with ß-lactam antibiotics in vitro and in vivo and that this combination is efficacious in a murine model of MRSA infection. Fluorescence microscopy localization studies reveal that synergy between these agents is likely to be elicited by the concomitant delocalization of their cognate drug targets (FtsZ and PBP2) in MRSA treated with PC190723. A 2.0 Å crystal structure of S. aureus FtsZ in complex with PC190723 identifies the compound binding site, which corresponds to the predominant location of mutations conferring resistance to PC190723 (PC190723(R)). Although structural studies suggested that these drug resistance mutations may be difficult to combat through chemical modification of PC190723, combining PC190723 with the ß-lactam antibiotic imipenem markedly reduced the spontaneous frequency of PC190723(R) mutants. Multiple MRSA PC190723(R) FtsZ mutants also displayed attenuated virulence and restored susceptibility to ß-lactam antibiotics in vitro and in a mouse model of imipenem efficacy. Collectively, these data support a target-based approach to rationally develop synergistic combination agents that mitigate drug resistance and effectively treat MRSA infections.


Subject(s)
Anti-Bacterial Agents/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , beta-Lactams/pharmacology , Animals , Anti-Bacterial Agents/therapeutic use , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Cell Division/drug effects , Crystallography, X-Ray , Cytoskeletal Proteins/antagonists & inhibitors , Cytoskeletal Proteins/chemistry , Cytoskeletal Proteins/metabolism , Disease Models, Animal , Drug Resistance, Bacterial/drug effects , Drug Synergism , Gene Regulatory Networks/genetics , Guanosine Diphosphate , Imipenem/pharmacology , Methicillin-Resistant Staphylococcus aureus/cytology , Methicillin-Resistant Staphylococcus aureus/pathogenicity , Mice , Microbial Sensitivity Tests , Mutation/genetics , Protein Structure, Secondary , Protein Transport/drug effects , Pyridines/chemistry , Pyridines/pharmacology , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Thiazoles/chemistry , Thiazoles/pharmacology , Virulence/drug effects , beta-Lactams/therapeutic use
4.
Peptides ; 26(8): 1323-30, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16042974

ABSTRACT

An autoradiographic study was conducted to determine whether kinin receptors are altered in the rat spinal cord in two experimental models of chronic hyperglycemia and insulin resistance. Sprague-Dawley rats were given 10% d-glucose in their drinking water alone or with insulin (9 mU/kg/min with osmotic pumps) for 4 weeks. Both groups and control rats were treated either with a normal chow diet or with an alpha-lipoic acid-supplemented diet as antioxidant therapy. After 4 weeks of treatment, glycemia, insulinemia, blood pressure, insulin resistance index, the production of superoxide anion in the aorta and the density of B2 receptor binding sites in the dorsal horn were significantly increased in the two models. These effects were prevented or attenuated by alpha-lipoic acid. In contrast, B2 receptor binding sites of most spinal cord laminae were increased in the glucose group only and were not affected by alpha-lipoic acid. Results show that chronic hyperglycemia associated with insulin resistance increases B1 and B2 receptor binding sites in the rat spinal cord through distinct mechanisms, including the oxidative stress for the B1 receptor.


Subject(s)
Insulin Resistance , Models, Animal , Receptor, Bradykinin B1/metabolism , Receptor, Bradykinin B2/metabolism , Spinal Cord/metabolism , Animals , Binding Sites , Blood Glucose/drug effects , Blood Glucose/metabolism , Blood Pressure/drug effects , Body Weight/drug effects , Glucose/administration & dosage , Insulin/administration & dosage , Insulin/metabolism , Male , Rats , Rats, Sprague-Dawley , Receptor, Bradykinin B1/drug effects , Receptor, Bradykinin B2/drug effects , Spinal Cord/drug effects , Superoxides/metabolism , Thioctic Acid/pharmacology
5.
Peptides ; 26(8): 1331-8, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15878793

ABSTRACT

A quantitative autoradiographic study was performed to determine whether kinin receptors are altered in the rat spinal cord in an experimental model of arterial hypertension under antioxidant therapy with alpha-lipoic acid. Sprague-Dawley rats were fed for 4 weeks with a normal chow diet or with an alpha-lipoic acid supplemented diet (1000 mg/kg feed), and treated for the last 2 weeks with angiotensin II (AT II) (200 ng/kg/min with an osmotic pump implanted s.c.). Control rats received either diet but not AT II. A 2-week administration of AT II increased significantly systolic blood pressure, the production of superoxide anion in the aorta and B1 receptor binding sites in the thoracic spinal dorsal horn. This treatment did not affect spinal B2 receptor binding sites, glycemia and insulinemia. The diet supplemented with alpha-lipoic acid reduced significantly the increase in systolic blood pressure, the production of aortic superoxide anion and prevented the increases of B1 receptor binding sites. Results show an association between the oxidative stress and the increases of B1 receptors and arterial blood pressure induced by AT II. Data also exclude the possibility that arterial hypertension is a primary mechanism leading to an increase of B2 receptor binding sites in the rat spinal cord.


Subject(s)
Angiotensin II/administration & dosage , Receptor, Bradykinin B1/drug effects , Receptor, Bradykinin B2/drug effects , Spinal Cord/metabolism , Thioctic Acid/pharmacology , Angiotensin II/pharmacology , Animals , Binding Sites/drug effects , Blood Glucose/drug effects , Blood Glucose/metabolism , Blood Pressure/drug effects , Body Weight/drug effects , Chronic Disease , Diet , Disease Models, Animal , Insulin/metabolism , Rats , Receptor, Bradykinin B1/metabolism , Receptor, Bradykinin B2/metabolism , Spinal Cord/drug effects , Superoxides/metabolism
6.
Neuroreport ; 15(16): 2463-6, 2004 Nov 15.
Article in English | MEDLINE | ID: mdl-15538175

ABSTRACT

Previous studies have reported cardiovascular and nociceptive responses after intrathecal injection of kinin B1 receptor (B1R) agonists in the model of streptozotocin (STZ)-diabetic rat (diabetic). The aim of this study was to measure the early up-regulation of B1R binding sites and mRNA in the thoracic spinal cord of diabetic and control rats. Data show significant increases of specific B1R binding sites in the dorsal horn of diabetic rats 2 days (+315%), 7 days (+303%) and 21 days (+181%) after STZ treatment. Levels of mRNA were significantly increased (+68%) at 2 and 7 days but not at 21 days. These data bring the first molecular evidence for an early up-regulation of B1R in the spinal cord of diabetic rat.


Subject(s)
Bradykinin/analogs & derivatives , Diabetes Mellitus, Experimental/metabolism , Receptor, Bradykinin B1/metabolism , Spinal Cord/metabolism , Animals , Blood Glucose/metabolism , Body Weight/physiology , Bradykinin/pharmacokinetics , Gene Expression Regulation/drug effects , In Situ Hybridization/methods , Iodine Isotopes/pharmacokinetics , Male , Protein Binding/drug effects , Protein Binding/physiology , RNA, Messenger/metabolism , Radiography/methods , Rats , Rats, Wistar , Receptor, Bradykinin B1/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Tetrahydroisoquinolines/pharmacokinetics , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...